Monetary Management Group Inc. lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 64.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,350 shares of the biopharmaceutical company’s stock after selling 4,300 shares during the period. Monetary Management Group Inc.’s holdings in Gilead Sciences were worth $176,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Grimes & Company Inc. boosted its position in shares of Gilead Sciences by 14.7% during the 4th quarter. Grimes & Company Inc. now owns 14,464 shares of the biopharmaceutical company’s stock worth $940,000 after acquiring an additional 1,850 shares in the last quarter. Samalin Investment Counsel LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $32,000. Alpha Omega Wealth Management LLC boosted its position in shares of Gilead Sciences by 2.4% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 54,106 shares of the biopharmaceutical company’s stock worth $3,516,000 after acquiring an additional 1,257 shares in the last quarter. IndexIQ Advisors LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Finally, Royal Bank of Scotland Group PLC boosted its position in shares of Gilead Sciences by 54.5% during the 4th quarter. Royal Bank of Scotland Group PLC now owns 28,685 shares of the biopharmaceutical company’s stock worth $1,864,000 after acquiring an additional 10,113 shares in the last quarter. Hedge funds and other institutional investors own 80.15% of the company’s stock.
NASDAQ GILD traded down $3.36 during mid-day trading on Thursday, reaching $73.82. 5,919,941 shares of the stock were exchanged, compared to its average volume of 19,633,348. Gilead Sciences, Inc. has a one year low of $60.89 and a one year high of $85.97. The stock has a 50 day simple moving average of $77.26 and a 200-day simple moving average of $71.19. The stock has a market cap of $92.60 billion, a P/E ratio of 18.98, a P/E/G ratio of 3.46 and a beta of 0.68. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The business had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter last year, the firm earned $1.67 earnings per share. Gilead Sciences’s quarterly revenue was up 5.1% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.4 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Friday, June 12th will be paid a dividend of $0.68 per share. This represents a $2.72 dividend on an annualized basis and a yield of 3.68%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s dividend payout ratio is presently 44.30%.
Several analysts recently issued reports on GILD shares. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research report on Tuesday, June 2nd. SVB Leerink upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $85.00 to $94.00 in a research report on Wednesday, June 3rd. ValuEngine lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. Robert W. Baird reissued a “hold” rating and issued a $75.00 price objective on shares of Gilead Sciences in a research note on Thursday, May 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, June 1st. Five investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $79.31.
In other Gilead Sciences news, EVP Brett A. Pletcher sold 13,210 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total value of $1,046,628.30. Following the completion of the sale, the executive vice president now directly owns 27,204 shares in the company, valued at $2,155,372.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $67.26, for a total transaction of $162,298.38. Following the completion of the sale, the director now owns 57,273 shares of the company’s stock, valued at $3,852,181.98. The disclosure for this sale can be found here. Insiders have sold 44,781 shares of company stock valued at $3,520,211 in the last three months. 0.13% of the stock is owned by insiders.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Why do companies pay special dividends?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.